Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 629

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 629
---
 $                       |        - |   |     | $    |          - |   |
| Non-cash investing and financing activities            |     |                         |          |   |     |      |            |   |
| Right of use asset - lease modification                |     | $                       |  245,243 |   |     | $    |          - |   |
| Operating lease obligation - lease modification        |     | $                       |  245,243 |   |     | $    |          - |   |
| Right of use asset - ASC 842 adoption                  |     | $                       |        - |   |     | $    |    262,985 |   |
| Operating lease obligation - ASC 842 adoption          |     | $                       |        - |   |     | $    |    289,665 |   |

The accompanying notes are an integral part of these financial statements.

| F-107 |

<div align='center'>CEREVAST MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS</div>

Note 1 – Organization and Description of the Business

Description of the Business

Cerevast Medical, Inc. (“Cerevast” or the “Company”), a Delaware corporation, is a clinical-stage medical device company based in Bothell, Washington, USA. The Company is committed to developing novel, first-in-class therapeutic solutions to restore health and improve the quality of life for patients that suffer from major diseases by leveraging their core expertise in the fields of ultrasound and microsphere technologies. The Company’s lead clinical stage programs are for the treatment of ischemic stroke and retinal vein occlusion, two devastating diseases with limited treatment options that effect millions of patients worldwide each year.

Going Concern

The Company does not have any current revenues. For the year ended December 31, 2023, the Company incurred an operating loss of $1,410,532 and has an accumulated deficit as of December 31, 2023 of $22,968,349. As of December 31, 2023, the Company had $76,957 in its operating bank accounts and a working capital deficit of $1,583,903. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity. The Company cannot provide any assurance that new financing will be available on commercially acceptable terms, if at all.

As described in Note 11, the Company is party to a potential business combination that,